Related Experiment Video
Updated: Jan 19, 2026

Evaluating the Impact of Hydraulic Fracturing on Streams using Microbial Molecular Signatures
Published on: April 4, 2021
A molecular signature for CD8+ T cells from visceral leishmaniasis patients
Bhawana Singh1, Shashi Bhushan Chauhan1, Rajiv Kumar2
1Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Abstract:
CD8+ T-cell function is compromised in chronic diseases such as visceral leishmaniasis (VL). However, little is known about the changes in gene expression that cause CD8+ T-cell dysfunction during VL. We used targeted transcriptional profiling of peripheral blood CD8+ T cells from VL patients pre- and post-anti-parasitic drug treatment, and compared them with the same cell population from healthy endemic controls to assess their activation, differentiation and functional status during disease. We found a predominance of downregulated immune genes in CD8+ T cells from VL patients. However, genes encoding several notable immune checkpoint molecules, including LAG-3, TIM-3 and CTLA-4, cytolytic molecules, such as granzymes A, B and H and perforin, as well as SOCS3, STAT1, JAK2 and JAK3 cytokine signalling genes were found to be increasingly expressed by VL patient CD8+ T cells. Additional studies confirmed increased expression of the inhibitory receptors LAG3 and TIM3 on VL patient CD8+ T cells, thereby identifying these molecules as potential targets to improve antigen-specific CD8+ T-cell responses during disease.
Related Concept Videos
09:11Evaluating the Impact of Hydraulic Fracturing on Streams using Microbial Molecular Signatures
07:29Reconstruction of Single-Cell Innate Fluorescence Signatures by Confocal Microscopy
06:42Real-Time In Vitro Migration Assay for Primary Murine CD8+ T Cells
12:09Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
06:07Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells
06:20An Assay for Cell Cycle Analysis of Antigen-Specific CD8+ T Cells

